Establishment Labs Holdings Inc

Establishment Labs Holdings, Inc. is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It generates income from customers in Europe, the Middle East, Latin America, and Asia. The firm's products include Motiva Implants, Motiva Flora Tissue Expander, Motiva Ergonomix, and Motiva Ergonomix2. The company was founded by Juan Jose Chacon-Quiros in 2004 and is headquartered in Alajuela, Costa Rica.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Establishment Labs posts strong revenue growth and sets ambitious targets

Establishment Labs reported strong revenue growth in Q4 2022 and outlined ambitious revenue guidance for 2023, supported by strategic product launches and market expansion initiatives.
While facing challenges in managing expenses and optimizing margins, the company's focus on growth opportunities and market transformation positions it for long-term success and achieving its revenue targets.
With a solid cash position, investments in new facilities, and a clear roadmap for future growth, Establishment Labs demonstrates resilience and strategic foresight in navigating the competitive landscape.

Establishment Labs (ESTA) reports robust Q1 revenue growth and global expansion

Establishment Labs Holdings Inc (ESTA) delivered strong revenue growth and strategic advancements in Q1 2023, positioning the company for future success.
While facing challenges in managing expenses and entering new markets, the company's focus on innovation and global expansion presents promising opportunities.
With a solid financial foundation and a clear growth strategy, ESTA is poised to capitalize on market demand and drive sustainable growth in the coming quarters.

Establishment Labs Holdings Inc reports strong Q2 growth and eyes expansion in China and Europe

Establishment Labs Holdings Inc's Q2 2023 performance showcased revenue growth and strategic advancements, despite challenges in profitability margins.
The company's focus on expanding into new markets, launching innovative products, and strengthening partnerships presents promising growth opportunities.
Maintaining revenue guidance, preparing for new launches, and addressing operational challenges position the company for a strong finish to 2023.

Establishment Labs maintains revenue amid global slowdown, eyes future growth

Establishment Labs faces challenges from a global slowdown in aesthetics procedures but sees opportunities in new markets and innovative products.
The company's focus on cost control and cash preservation aligns with expectations of positive EBITDA and cash flow in the future.
Key strengths include FDA clearances, positive study outcomes, and confidence in growth prospects beyond 2023.

Establishment Labs (ESTA) reports robust Q4 revenue and eyes global expansion

Establishment Labs Holdings Inc (ESTA) demonstrated strong revenue growth and cost management in Q4 2023.
The company faces challenges in gross profit and cash utilization but is poised for improved margins and profitability in 2024 and beyond.
Opportunities lie in global expansion, market penetration with innovative products, and a focus on achieving positive cash flow in the near future.

Establishment Labs reports strong Q1 revenue and eyes global growth

Establishment Labs Holdings Inc showed strong Q1 performance with revenue of $37.2 million.
The company aims to achieve positive adjusted EBITDA by end of 2024 and positive cash flow by end of 2025.
Progress in FDA approvals, market diversification, and strategic expansion plans are key strengths.
Challenges include addressing net losses, achieving positive EBITDA, and upcoming FDA inspection.

Establishment Labs Holdings Inc reports strong Q2 performance and eyes U.S. and China growth

Establishment Labs Holdings Inc demonstrated strong revenue growth and progress towards profitability in Q2 2024.
While facing challenges in Latin America, the company is capitalizing on opportunities in the U.S. and China markets.
With a focus on new product launches and improving gross margins, the company is poised for future growth and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of -35.29% and -0.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Lags Revenue Estimates

Shares of Establishment Labs Hldgs (NASDAQ:ESTA) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 14.81% year over year to ($0.23), which missed the estimate of ($0.19).

Recap: Establishment Labs Q4 Earnings

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced its financial results for the fourth quarter and full year ended December 31, 2020 and provided initial 2021 guidance. Fourth Quarter Highlights and Outlook Fourth quarter worldwide sales of $27.0 million, an increase of 11% year-over-year and a new quarterly record; consiste

Establishment Labs Reports Fourth Quarter and Full Year 2020 Financial Results; Record Fourth Quarter Revenue of $27.0 Million

Establishment Labs Hldgs (NASDAQ:ESTA) announces its next round of earnings this Wednesday, March 10. Here is Benzinga's look at Establishment Labs Hldgs's Q4 earnings report.

Establishment Labs Hldgs Earnings Preview

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, announced today that Raj Denhoy has been appointed Head of Strategy and Investor Relations. Mr. Denhoy will join the executive team at Establishment Labs to help define and execute the company's corporate strategy and to communicate that vision to investors and other stakeholders. Mr. Denhoy

Establishment Labs Announces Raj Denhoy Has Joined the Company as Head of Strategy and Investor Relations

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended December 31, 2020 before the market opens on Wednesday, March 10, 2021, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 376-9925 (U.S. and Canada)

Establishment Labs to Announce Fourth Quarter 2020 Financial Results on March 10

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the Cowen 41st Annual Healthcare Conference, which is being held March 1-4, 2021. Mr. Chacón-Quirós and Mrs. Gaeta are scheduled to speak to conference attendees at 9:50 a

Establishment Labs Announces Participation in the Cowen 41st Annual Healthcare Conference

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, is hosting a virtual investor event today, February 9, 2021, 1:00 - 2:30 p.m. ET to discuss its Motiva MIA system for minimally invasive breast augmentation. The Motiva MIA study demonstrates a significant advancement in breast aesthetics. Relative to traditional augmentation surgery, MIA of

Establishment Labs Hosts Investor Event for its Motiva MIA® System for Minimally Invasive Augmentation

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference, which is being held February 17-19, 2021. Mr. Chacón-Quirós and Mrs. Gaeta are sche

Establishment Labs Announces Participation in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

As of late, it has definitely been a great time to be an investor in Establishment Labs Holdings (ESTA).

Establishment Labs' (ESTA) Shares March Higher, Can It Continue?

Establishment Labs (ESTA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Establishment Labs (ESTA) Catches Eye: Stock Jumps 5.7%

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced it will host a virtual investor event on Feb. 9, 2021 to discuss its Motiva Mia® system for minimally invasive augmentation, which includes the Motiva Ergonomix2 Diamond® breast implant. The Motiva Mia system is designed to offer a minimally invasive breast enhancement proced

Establishment Labs to Host Investor Event Featuring Its Motiva Mia System

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós will participate in the 39th Annual J.P. Morgan Healthcare Conference, which is being held January 11-14, 2021. Mr. Chacón-Quirós is scheduled to speak to conference attendees at 4:30 pm ET on Thursday, January 14, 2021. A live web

Establishment Labs Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today reported preliminary revenue and cash figures for the fourth quarter and fiscal year ended December 31, 2020. Preliminary and unaudited revenue for the fourth quarter 2020 is expected to be in the range of $26.5 million to $27.5 million, reflecting approximately 10% to 13% growth compa

Establishment Labs Reports Preliminary Results for Fourth Quarter and Fiscal Year 2020

SANTA BARBARA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced it recently received Institutional Review Board (IRB) approval to initiate a patient series in Costa Rica to study its Motiva Mia® system for minimally invasive augmentation, which includes the Motiva Ergonomix2 Diamond® breast implant, and has completed the procedure in the first 21 patients in the study.

Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica

Establishment Labs Holdings, Inc. (ESTA) CEO Juan José Chacón Quirós on Q3 2020 Results - Earnings Call Transcript

SANTA BARBARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced its financial results for the third quarter ended September 30, 2020.

Establishment Labs Reports Third Quarter 2020 Financial Results

SANTA BARBARA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today reported strong preliminary revenue and cash figures for the quarter ended September 30, 2020.

Establishment Labs Reports Preliminary Third Quarter Revenue and Cash Balance

Event to Feature Members of Company’s Medical and Scientific Advisory Boards and U.S. IDE Medical Director Event to Feature Members of Company’s Medical and Scientific Advisory Boards and U.S. IDE Medical Director

Establishment Labs to Celebrate 10 Years of Motiva Safety Data at Plastic Surgeon Virtual Symposium

SANTA BARBARA, Calif., Sept.  25, 2020  (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it has finalized an amendment to its distribution agreement with Puregraft LLC for Puregraft’s line of products for autologous adipose tissue harvesting and redistribution. This amended agreement, which now will continue through the end of 2022, modifies the terms of the original distribution agreement that had terminated earlier this year.

Establishment Labs Finalizes Distribution Agreement with Puregraft LLC

SANTA BARBARA, Calif., Sept.  21, 2020  (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, announced today that a recently published independent study concluded that the hybrid breast reconstruction approach using Motiva® Ergonomix implants improved outcomes in implant-based breast reconstructions.

Establishment Labs Announces Independent Publication Detailing New Advancements in Hybrid Breast Reconstruction Technique Using Motiva Ergonomix Implants

NEW YORK, Sept.  02, 2020  (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the 2020 Wells Fargo Virtual Healthcare Conference, which is being held September 9-10, 2020. Mr. Chacón-Quirós and Ms. Gaeta are scheduled to speak to conference attendees at 2:00 pm ET on Wednesday, September 9, 2020.

ESTA Announces Participation in the Wells Fargo Virtual Healthcare Conference

Establishment Labs Holdings Inc. (ESTA) CEO Juan José Chacón-Quirós on Q2 2020 Results - Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Earnings Preview: Establishment Labs Holdings Inc. (ESTA) Q2 Earnings Expected to Decline

NEW YORK, July  23, 2020  (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (Nasdaq: ESTA), a medical technology company focused on Women’s Health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended June 30, 2020 after the market closes on Thursday, August 6, 2020, and will host a conference call at 5:30 pm ET that day to discuss those results.

News for Establishment Labs Holdings Inc Stock (ESTA)